

Heat-shock protein 27 (HSP27) not just a biomarker of cardiac and renal diseases

Kamila Bołtuć-Dziugiel¹, Robert Dziugiel¹, Andrzej Jaroszyński¹

Collegium Medicum, Jan Kochanowski University in Kielce, Poland

Abstract

Heat-shock proteins (HSPs) are a large family of conserved chaperone proteins which provide cell protection from various forms of stress including inflammation, hypoxia, ischaemia, and apoptosis. Heat-shock protein 27 (HSP27) is a member of a small molecular weight HSP family and it has recently been connected with cardiac and renal disorders. Several studies stated that HSP27 can be a reliable predictor of cardiac events in patients with chronic heart failure. Moreover, there is a strong inverse relationship between HSP27 level and atherosclerosis. Interestingly, the HSP27 level in atherosclerosis plaques was significantly lower compared to healthy arteries. Additionally, HSP27 was linked with atrial fibrillation (AF) and acute chest pain. Various studies also reported HSP27's usefulness in renal disorders. HSP27 seems to be an independent predictor of not only cardiovascular mortality but also sudden cardiac death (SCD) among haemodialysed (HD) patients. Collaterally HSP27 was proposed as a marker of chronic kidney disease, contrast-induced acute kidney injury (AKI) as well as AKI associated with liver ischaemia-reperfusion injury. Observations from studies conducted to date suggest that HSP27 may be a valuable marker for cardiovascular and nephrological diseases and even a possible therapeutic target. However, to fully understand the role of HSP27 in these diseases, further studies are required.

Keywords: heat-shock protein 27; atherosclerosis; acute kidney injury; atrial fibrillation

Acta Angiol 2024; 30, 3: 106–111

Introduction

Heat-shock proteins (HSPs) are a family of proteins found in all cells of organisms, and they play a crucial role in protecting cells against various forms of stress. The activation of HSPs can be found not only due to elevated temperature but also other stressors such as inflammation, hypoxia, ischaemia, nutritional deficiencies or toxins. They help in maintaining the proper folding of other cellular proteins, prevent protein aggregation, control the cell cycle, assist in the repair of damaged proteins, and protect cells from oxidative

stress as well as apoptosis [1–4]. The effect of HSP27 on tissues affected by stress or trauma is shown in Figure 1.

Depending on the molecular weight of HSPs, they are classified into different families. Heat-shock protein 27 (HSP27) is a member of the small molecular weight HSP family. It is considered to be one of the most important low molecular weight HSPs and is partially produced in cardiomyocytes, endothelial cells, and renal medulla [5–8]. Several commercial assays are commonly used to measure serum HSP27. Most of these assays are enzyme-linked immunosorbent assays (ELISAs) that utilize antibodies against HSP27. Although

Address for correspondence: Andrzej Jaroszyński MD, PhD, Collegium Medicum, Jan Kochanowski University in Kielce, al. IX Wieków 19A, 25–317 Kielce, Poland, e-mail: jaroszynskiaj@interia.pl

Received: 09.09.2023 Accepted: 08.08.2024 Early publication date: 24.10.2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.




Figure 1. Presents the simplified HSP27 effects on the tissues influenced by stress or trauma

this technique offers valuable information on protein concentrations and can be extremely sensitive, it also has some well-known limitations. It is worth noting that results from commercial clinical HSP27 ELISAs may vary due to differences in antibodies and calibrators used, resulting in considerable measurement variability. Additionally, this technique involves protein horseradish peroxidase (HRP) enzymes that serve as amplifiers. These enzymes are sensitive to reaction conditions such as time, temperature, and pH, which restrict the universal application of the enzyme-based amplification technique leading to false positive results [9]. Liquid chromatography-tandem mass spectrometry-based targeted proteomics serves as an alternative technique. It enables the quantification of the proteins with high quantitative accuracy, reproducibility, and a broad dynamic range [10]. HSP27 was previously related to neurodegenerative diseases [11], however recently there has been a growing interest in linking it with cardiac and renal diseases [5–8, 12].

HSP27 and cardiac diseases

HSP27 has seemed to exert a cardioprotective effect and has been emerging as a potential biomarker and a therapeutic target of cardiovascular disorders [5, 7, 12, 13].

There was a recent study suggesting that HSP27 may be a useful biomarker of cardiovascular death related to chronic heart failure (HF) or sudden HF hospitalization [14]. Chronic HF is a condition in which, as a result of cardiac dysfunction, there is a reduction in the minute capacity of the heart in relation to the metabolic demands of the tissues of the body [15]. Trax-

ler et al. included 134 patients with chronic HF in the study. During a follow-up 33% of patients experienced cardiac events. Statistical analysis showed that HSP27 levels above the median stated for increased risk of an event even after adjustment for factors such as age, gender, aetiology, smoking status and others. According to Traxler, increased levels of HSP27 are due to the myocardium's response to ischaemia-reperfusion injury with the use of Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4). This study proved that HSP27 can be a strong independent predictor of cardiac events in patients with chronic HF [14].

Atherosclerosis is a common condition involving the accumulation of lipids and extracellular matrix material as plaques in the arteries. Over time, it can lead to narrowing and stiffening of the arteries, reducing the blood flow, and consequently causing cardiovascular diseases [16–18]. Martin-Ventura et al. stated that HSP27, among other differentially secreted proteins, can be characterized as a potential biomarker of atherosclerosis. They suggested that HSP27 expression was decreased in atherosclerotic plaques as a result of its degradation by proteolysis contrary to healthy arteries [17]. According to Wick, the observation of high HSP27 expression in the normal-appearing area adjacent to the atherosclerotic plaque may suggest that the inflammatory processes are particularly active in this region. Consequently, there can be a decrease in HSP27 expression toward the atherosclerotic core due to inversely increased proteolytic activity in this region of the plaque [18]. Similar findings were stated in the study by Park et al. Additionally, their study showed a significant increase in serum HSP27 antigen concentrations in patients with acute coronary syndro-

me (ACS) which were not related to cardiovascular disease risk factors [19]. Jaroszyński et al. stated the strong inverse association between serum values of HSP27 and carotid atherosclerosis. Increased serum HSP27 levels mitigated the progression of atherosclerosis and induced a transformation in plaques towards a more stable morphology [12]. These studies proved that HSP27 can be used in clinical practice not only as a strong predictor but also as a possible therapeutic target of atherosclerosis.

Talkhi et al. [8] in their study aimed to characterize the variables associated with serum anti-HSP27 antibody titres which can become a potential biomarker of inflammation in patients with cardiovascular disease (CVD), and consequently improve strategies for managing CVD. Authors revealed that factors associated with anti-HSP27 were, among others, pro-oxidant-antioxidant balance (PAB), physical activity level (PAL), platelet distribution width (PDW), systolic blood pressure (SBP), age, red cell distribution width (RDW), neutrophils to lymphocytes ratio (NLR), platelet count (PLT), glucose, cholesterol, red blood cells (RBC). Of the above factors, PAB presented the strongest correlation and serum anti-HSP27 antibody titre prediction.

Interestingly Shams et al. [20] showed that IgG anti-HSP27 antibodies levels were increased in patients with acute chest pain. This growth was strongly associated with only age and hypertension as cardiovascular risk factors and weakly with diabetes in patients with acute coronary syndrome (ACS). Moreover, some studies have suggested that following ischaemia-reperfusion accident HSP27 level is increased in cardiac myocytes [21, 22].

The most common cardiac arrhythmia, which tends to grow more enduring as time progresses, is atrial fibrillation (AF). Because AF provokes myocyte stress and structural cell changes, Brundel et al. [23] aimed to characterize if and which HSPs may protect cells from myolysis and consequently prevent AF progression. In their study on the HL-1 cell model for AF increased level of HSP27 alone was responsible for attenuating myolysis. Furthermore, they extended their results to human AF, which showed a highly increased expression of HSP27 in the atrial appendages of patients with paroxysmal AF. In addition, Marion et al. in their study investigated the role of HSP27 in AF staging, however, no significant association was observed between HSP level and AF stages or AF recurrence. Nonetheless, serum samples taken from patients who experienced AF recurrence within a year after pulmonary vein isolation (PVI) exhibited elevated levels of HSP27. This implied that HSP27 could serve as a predictive marker for AF recurrence following ablative therapy [24]. Additionally, in patients who underwent arrhythmia surgery, HSP27

can also be a predictor of AF recurrence according to van Marion et al. [25]. Lastly, Kargari et al. [26] found that obese patients had significantly higher levels of HSP27 anti-body titres than the nonobese group, which could potentially suggest that HSP27 can be a risk biomarker of cardiovascular diseases.

There are only a few studies that examined the possible HSP27's usefulness in treating cardiovascular diseases. In the study from 1999, Dillmann proposed a model where HSP27 could provide a protective effect against simulated ischaemia. The author suggested a model in which proteins that have not yet achieved their final folding state bind to the exterior of large oligomeric small heat shock protein complexes, which act as a sheltered environment. Once ischaemia is resolved, these proteins can be released, allowing them to attain their final folding state and resume their normal activity in cells that have recovered from ischaemic injury [27]. Additionally, Brundel et al. noticed that increased HSP27 expression protects myocytes from tachy-pacing-induced myolysis. The HSP response, which is temporarily activated in patients with AF, appears to diminish over time, losing its capacity to prevent structural changes like myolysis and consequently may contribute to the progression of AF. That is why future research is needed to evaluate the therapeutic potential of drugs that may enhance the HSP response in treating AF [23]. Despite these promising results, HSP27's application in treating other cardiovascular diseases remains underdeveloped. Therapeutic protocols aimed at improving conditions such as atherosclerosis, ischaemic heart disease, cardiac arrhythmias, and cardiomyopathies are required to fully understand the usefulness of HSP27.

HSP27 and renal diseases

Results of various studies suggest the utility of HSP27 in the diagnosis and treatment of kidney diseases.

Jaroszyński et al. evaluated the predictive value of HSP27 in mortality and factors associated with HSP27 in a group of haemodialysed (HD) patients. 202 HD patients and 42 controls were enrolled on the study. The main discovery was that there was no discernible difference in serum HSP27 between HD patients and controls. Moreover, decreased levels of HSP27 emerged as a standalone predictor of cardiovascular mortality and sudden cardiac death (SCD), among HD patients [12]. Additionally, Jaroszyński et al. [28] in the other study revealed a significant connection between low HSP27 levels and widened spatial QRS-T angle, which reflects increased heterogeneity of myocardial action potential. The spatial QRS-T angle is the angle between the vectors of ventricular depolarization and repolarization. It is considered to be the strong,

ECG-derived predictor for cardiac events and SCD in the general population and the high clinical risk group of patients, including HD patients [28, 29].

Lebherz-Eichinger et al. [30] have shown in their article from 2012 that patients with chronic kidney disease (CKD) had increased HSP27 levels both in serum and in the urine. They also suggested that it could be an easily obtainable potential marker of the course of CKD, and consequently treatment response. Elevated serum HSP27 level was noticed in pre-dialysis patients which is in agreement with the study from Musiał et al. [31]. Their study was conducted on the paediatric population suffering from CKD and undergoing chronic dialysis. The results have shown that children with CKD are more prone to HSP27 malfunction with HD as the exacerbating factor [31].

The common cause of hospital-acquired acute kidney injury (AKI) is contrast-induced AKI associated with the use of iodine-based radiographic contrast media. The underlying mechanisms of the development of contrast-induced AKI include ischaemia reperfusion injury, among others [32–35]. Elevated levels of HSP27 are typically found within the renal medulla as a reaction to hypoxia and oxidative stress. It seems that HSP27 may exhibit a protective effect against contrast-induced AKI. Previously conducted studies have suggested that HSP27 averts damage and reestablishes the regular functioning of kidney cells after an episode of reperfusion injury [5, 36, 37]. Jaroszyński et al. [38] conducted a study which revealed that low HSP27 level is a reliable and independent predictor of contrast-induced AKI in patients submitted to percutaneous coronary interventions (PCI).

Moreover, it was demonstrated in animal models that overexpression of HSP27 can protect liver cells from injury and AKI associated with liver ischaemia-reperfusion injury in vivo [39]. In addition, Guo et al. revealed HSP27 overexpression in the renal tissues from animal models after acute ischaemic kidney damage. The HSP27 peak level was observed after 6 hours post-reperfusion [40].

Conclusions

The present summary emphasizes some of the recent data on the usefulness of HSP27. HSP27 has been emerging as a reliable biomarker of cardiac disorders, such as atherosclerosis or AF. Moreover, it has seemed to be an independent predictor of cardiovascular mortality and SCD among HD patients, a potential marker of CKD course as well as protect the renal tissue from the development of contrast-induced AKI. Taking it into account HSP27 may become a likely therapeutic target, especially of atherosclerosis in the near future.

Nevertheless, further studies on a larger number of subjects are required to expand our knowledge about this remarkable and promising protein.

Article information and declarations

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Funding: None.

Acknowledgements: None.

Conflict of interest: The authors declare that there is no conflict of interest.

References

1. Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. *Fibrogenesis Tissue Repair*. 2012; 5(1): 7, doi: [10.1186/1755-1536-5-7](https://doi.org/10.1186/1755-1536-5-7), indexed in Pubmed: [22564335](https://pubmed.ncbi.nlm.nih.gov/22564335/).
2. Rodríguez-Iturbe B, Johnson RJ. Heat shock proteins and cardiovascular disease. *Physiol Int*. 2018; 105(1): 19–37, doi: [10.1556/2060.105.2018.1.4](https://doi.org/10.1556/2060.105.2018.1.4), indexed in Pubmed: [29602292](https://pubmed.ncbi.nlm.nih.gov/29602292/).
3. Bakthisaran R, Tangirala R, Rao ChM. Small heat shock proteins: Role in cellular functions and pathology. *Biochim Biophys Acta*. 2015; 1854(4): 291–319, doi: [10.1016/j.bbapap.2014.12.019](https://doi.org/10.1016/j.bbapap.2014.12.019), indexed in Pubmed: [25556000](https://pubmed.ncbi.nlm.nih.gov/25556000/).
4. Hu C, Yang J, Qi Z, et al. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. *MedComm (2020)*. 2022; 3(3): e161, doi: [10.1002/mco2.161](https://doi.org/10.1002/mco2.161), indexed in Pubmed: [35928554](https://pubmed.ncbi.nlm.nih.gov/35928554/).
5. Martínez-Laorden E, Navarro-Zaragoza J, Milanés MV, et al. Cardiac Protective Role of Heat Shock Protein 27 in the Stress Induced by Drugs of Abuse. *Int J Mol Sci*. 2020; 21(10), doi: [10.3390/ijms21103623](https://doi.org/10.3390/ijms21103623), indexed in Pubmed: [32455528](https://pubmed.ncbi.nlm.nih.gov/32455528/).
6. Ghayour-Mobarhan M, Saber H, Ferns GAA. The potential role of heat shock protein 27 in cardiovascular disease. *Clin Chim Acta*. 2012; 413(1-2): 15–24, doi: [10.1016/j.cca.2011.04.005](https://doi.org/10.1016/j.cca.2011.04.005), indexed in Pubmed: [21514288](https://pubmed.ncbi.nlm.nih.gov/21514288/).
7. Junho CV, Azevedo CA, da Cunha RS, et al. Heat Shock Proteins: Connectors between Heart and Kidney. *Cells*. 2021; 10(8), doi: [10.3390/cells10081939](https://doi.org/10.3390/cells10081939), indexed in Pubmed: [34440708](https://pubmed.ncbi.nlm.nih.gov/34440708/).
8. Talkhi N, Nooghabi MJ, Esmaily H, et al. Prediction of serum anti-HSP27 antibody titers changes using a light gradient boosting machine (LightGBM) technique. *Sci Rep*. 2023; 13(1): 12775, doi: [10.1038/s41598-023-39724-z](https://doi.org/10.1038/s41598-023-39724-z), indexed in Pubmed: [37550399](https://pubmed.ncbi.nlm.nih.gov/37550399/).
9. De AK, Roach SE. Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. *J Immunoassay Immunochem*. 2004; 25(2): 159–170, doi: [10.1081/ias-120030525](https://doi.org/10.1081/ias-120030525), indexed in Pubmed: [15162919](https://pubmed.ncbi.nlm.nih.gov/15162919/).
10. Marx V. Targeted proteomics. *Nat Methods*. 2013; 10(1): 19–22, doi: [10.1038/nmeth.2285](https://doi.org/10.1038/nmeth.2285), indexed in Pubmed: [23547293](https://pubmed.ncbi.nlm.nih.gov/23547293/).
11. Holguin BA, Hildenbrand ZL, Bernal RA. Insights Into the Role of Heat Shock Protein 27 in the Development of Neurodegeneration. *Front Mol Neurosci*. 2022; 15: 868089, doi: [10.3389/fnmol.2022.868089](https://doi.org/10.3389/fnmol.2022.868089), indexed in Pubmed: [35431800](https://pubmed.ncbi.nlm.nih.gov/35431800/).

12. Jaroszyński A, Jaroszyńska A, Zaborowski T, et al. Serum heat shock protein 27 levels predict cardiac mortality in hemodialysis patients. *BMC Nephrol.* 2018; 19(1): 359, doi: [10.1186/s12882-018-1157-1](https://doi.org/10.1186/s12882-018-1157-1), indexed in Pubmed: [30558560](https://pubmed.ncbi.nlm.nih.gov/30558560/).
13. Zhang HL, Jia KY, Sun Da, et al. Protective effect of HSP27 in atherosclerosis and coronary heart disease by inhibiting reactive oxygen species. *J Cell Biochem.* 2019; 120(3): 2859–2868, doi: [10.1002/jcb.26575](https://doi.org/10.1002/jcb.26575), indexed in Pubmed: [29232010](https://pubmed.ncbi.nlm.nih.gov/29232010/).
14. Traxler D, Lainscak M, Simader E, et al. Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients. *Clin Chim Acta.* 2017; 473: 127–132, doi: [10.1016/j.cca.2017.08.028](https://doi.org/10.1016/j.cca.2017.08.028), indexed in Pubmed: [28844461](https://pubmed.ncbi.nlm.nih.gov/28844461/).
15. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016; 37(27): 2129–2200, doi: [10.1093/eurheartj/ehw128](https://doi.org/10.1093/eurheartj/ehw128), indexed in Pubmed: [27206819](https://pubmed.ncbi.nlm.nih.gov/27206819/).
16. Shan R, Liu N, Yan Y, et al. Apoptosis, autophagy and atherosclerosis: Relationships and the role of Hsp27. *Pharmacol Res.* 2021; 166: 105169, doi: [10.1016/j.phrs.2020.105169](https://doi.org/10.1016/j.phrs.2020.105169), indexed in Pubmed: [33053445](https://pubmed.ncbi.nlm.nih.gov/33053445/).
17. Martin-Ventura JL, Duran MC, Blanco-Colio LM, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. *Circulation.* 2004; 110(15): 2216–2219, doi: [10.1161/01.CIR.0000136814.87170.B1](https://doi.org/10.1161/01.CIR.0000136814.87170.B1), indexed in Pubmed: [15249501](https://pubmed.ncbi.nlm.nih.gov/15249501/).
18. Wick G. The heat is on: heat-shock proteins and atherosclerosis. *Circulation.* 2006; 114(9): 870–872, doi: [10.1161/CIRCULATIONAHA.106.647875](https://doi.org/10.1161/CIRCULATIONAHA.106.647875), indexed in Pubmed: [16940202](https://pubmed.ncbi.nlm.nih.gov/16940202/).
19. Park HK, Park EC, Bae SW, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. *Circulation.* 2006; 114(9): 886–893, doi: [10.1161/CIRCULATIONAHA.105.541219](https://doi.org/10.1161/CIRCULATIONAHA.105.541219), indexed in Pubmed: [16923754](https://pubmed.ncbi.nlm.nih.gov/16923754/).
20. Shams S, Shafi S, Bodman-Smith K, et al. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. *Clin Chim Acta.* 2008; 395(1–2): 42–46, doi: [10.1016/j.cca.2008.04.026](https://doi.org/10.1016/j.cca.2008.04.026), indexed in Pubmed: [18501705](https://pubmed.ncbi.nlm.nih.gov/18501705/).
21. Vander Heide RS. Increased expression of HSP27 protects canine myocytes from simulated ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol.* 2002; 282(3): H935–H941, doi: [10.1152/ajpheart.00660.2001](https://doi.org/10.1152/ajpheart.00660.2001), indexed in Pubmed: [11834489](https://pubmed.ncbi.nlm.nih.gov/11834489/).
22. Jin C, Cleveland JC, Ao L, et al. Human myocardium releases heat shock protein 27 (HSP27) after global ischemia: the proinflammatory effect of extracellular HSP27 through toll-like receptor (TLR)-2 and TLR4. *Mol Med.* 2014; 20(1): 280–289, doi: [10.2119/molmed.2014.00058](https://doi.org/10.2119/molmed.2014.00058), indexed in Pubmed: [24918749](https://pubmed.ncbi.nlm.nih.gov/24918749/).
23. Brundel BJ, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. *J Mol Cell Cardiol.* 2006; 41(3): 555–562, doi: [10.1016/j.yjmcc.2006.06.068](https://doi.org/10.1016/j.yjmcc.2006.06.068), indexed in Pubmed: [16876820](https://pubmed.ncbi.nlm.nih.gov/16876820/).
24. Marion DM, Lanteris EAH, Ramos KS, et al. Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation. *Cells.* 2020; 9(9), doi: [10.3390/cells9092105](https://doi.org/10.3390/cells9092105), indexed in Pubmed: [32947824](https://pubmed.ncbi.nlm.nih.gov/32947824/).
25. van Marion DMS, Ramos KS, Lanteris EAH, et al. Atrial heat shock protein levels are associated with early postoperative and persistence of atrial fibrillation. *Heart Rhythm.* 2021; 18(10): 1790–1798, doi: [10.1016/j.hrthm.2021.06.1194](https://doi.org/10.1016/j.hrthm.2021.06.1194), indexed in Pubmed: [34186247](https://pubmed.ncbi.nlm.nih.gov/34186247/).
26. Kargari M, Tavassoli S, Avan A, et al. Relationship between serum anti-heat shock protein 27 antibody levels and obesity. *Clin Biochem.* 2017; 50(12): 690–695, doi: [10.1016/j.clinbiochem.2017.02.015](https://doi.org/10.1016/j.clinbiochem.2017.02.015), indexed in Pubmed: [28237841](https://pubmed.ncbi.nlm.nih.gov/28237841/).
27. Dillmann WH. Small Heat Shock Proteins an Protection. *Proteins n d.* : 618–20.
28. Jaroszyński A, Schlegel TT, Mosiewicz J, et al. Heat Shock Protein 27 Levels Predict Myocardial Inhomogeneities in Hemodialysis Patients. *Mediators Inflamm.* 2022; 2022: 5618867, doi: [10.1155/2022/5618867](https://doi.org/10.1155/2022/5618867), indexed in Pubmed: [35633658](https://pubmed.ncbi.nlm.nih.gov/35633658/).
29. Kardys I, Kors JA, van der Meer IM, et al. Spatial QRS-T angle predicts cardiac death in a general population. *Eur Heart J.* 2003; 24(14): 1357–1364, doi: [10.1016/s0195-668x\(03\)00203-3](https://doi.org/10.1016/s0195-668x(03)00203-3), indexed in Pubmed: [12871693](https://pubmed.ncbi.nlm.nih.gov/12871693/).
30. Leberz-Eichinger D, Ankersmit HJ, Hacker S, et al. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. *Clin Chim Acta.* 2012; 413(1–2): 282–286, doi: [10.1016/j.cca.2011.10.010](https://doi.org/10.1016/j.cca.2011.10.010), indexed in Pubmed: [22032827](https://pubmed.ncbi.nlm.nih.gov/22032827/).
31. Musiał K, Zwolińska D. Hsp27 as a marker of cell damage in children on chronic dialysis. *Cell Stress Chaperones.* 2012; 17(6): 675–682, doi: [10.1007/s12192-012-0339-1](https://doi.org/10.1007/s12192-012-0339-1), indexed in Pubmed: [22528051](https://pubmed.ncbi.nlm.nih.gov/22528051/).
32. Krasinski Z, Krasinska B, Olszewska M, et al. Acute Renal Failure/Acute Kidney Injury (AKI) Associated with Endovascular Procedures. *Diagnostics (Basel).* 2020; 10(5), doi: [10.3390/diagnostics10050274](https://doi.org/10.3390/diagnostics10050274), indexed in Pubmed: [32370193](https://pubmed.ncbi.nlm.nih.gov/32370193/).
33. Andreucci M, Faga T, Pisani A, et al. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. *ScientificWorldJournal.* 2014; 2014: 823169, doi: [10.1155/2014/823169](https://doi.org/10.1155/2014/823169), indexed in Pubmed: [25525625](https://pubmed.ncbi.nlm.nih.gov/25525625/).
34. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv.* 2014; 7(1): 1–9, doi: [10.1016/j.jcin.2013.06.016](https://doi.org/10.1016/j.jcin.2013.06.016), indexed in Pubmed: [24456715](https://pubmed.ncbi.nlm.nih.gov/24456715/).
35. Pistoletti V, Regolisti G, Morabito S, et al. Contrast medium induced acute kidney injury: a narrative review. *J Nephrol.* 2018; 31(6): 797–812, doi: [10.1007/s40620-018-0498-y](https://doi.org/10.1007/s40620-018-0498-y), indexed in Pubmed: [29802583](https://pubmed.ncbi.nlm.nih.gov/29802583/).
36. O'Neill S, Harrison EM, Ross JA, et al. Heat-shock proteins and acute ischaemic kidney injury. *Nephron Exp Nephrol.* 2014; 126(4): 167–174, doi: [10.1159/000363323](https://doi.org/10.1159/000363323), indexed in Pubmed: [24923736](https://pubmed.ncbi.nlm.nih.gov/24923736/).
37. Marquez E, Sadowski E, Reese S, et al. Serum HSP27 is associated with medullary perfusion in kidney allografts. *J Nephrol.* 2012; 25(6): 1075–1080, doi: [10.5301/jn.5000099](https://doi.org/10.5301/jn.5000099), indexed in Pubmed: [22383348](https://pubmed.ncbi.nlm.nih.gov/22383348/).
38. Jaroszyński A, Zaborowski T, Głuszek S, et al. Heat Shock Protein 27 Is an Emerging Predictor of Contrast-Induced Acute

- Kidney Injury on Patients Subjected to Percutaneous Coronary Interventions. *Cells*. 2021; 10(3), doi: [10.3390/cells10030684](https://doi.org/10.3390/cells10030684), indexed in Pubmed: [33808831](https://pubmed.ncbi.nlm.nih.gov/33808831/).
39. Park SW, Chen SWC, Kim M, et al. Human heat shock protein 27-overexpressing mice are protected against acute kidney injury after hepatic ischemia and reperfusion. *Am J Physiol Renal Physiol*. 2009; 297(4): F885–F894, doi: [10.1152/ajprenal.00317.2009](https://doi.org/10.1152/ajprenal.00317.2009), indexed in Pubmed: [19656912](https://pubmed.ncbi.nlm.nih.gov/19656912/).
40. Guo Q, Du X, Zhao Y, et al. Ischemic postconditioning prevents renal ischemia reperfusion injury through the induction of heat shock proteins in rats. *Mol Med Rep*. 2014; 10(6): 2875–2881, doi: [10.3892/mmr.2014.2641](https://doi.org/10.3892/mmr.2014.2641), indexed in Pubmed: [25322861](https://pubmed.ncbi.nlm.nih.gov/25322861/).